Efficacy of local treatment for isolated liver metastasis after pancreatectomy in pancreatic ductal adenocarcinoma: A propensity score‐matched analysis

Abstract

AbstractBackgroundAlthough attempts of local treatment for isolated liver recurrence in patients with pancreatic ductal adenocarcinoma (PDAC) have increased, the efficacy remains unclear. Therefore, we aimed to evaluate the effect of local treatment for recurrent liver lesions after pancreatectomy on the survival of patients with PDAC.MethodsPatients who were diagnosed with isolated liver recurrence after pancreatectomy at a high‐volume center were included. We classified these patients based on the treatment options after recurrence and performed propensity score matching to minimize confounding.ResultsMedian with interquartile range survival after recurrence was significantly longer for patients who underwent local treatment for recurrent liver lesions plus chemotherapy (22.0 [17.0–29.0] months) than those treated with chemotherapy alone (13.0 [7.0–21.0] months, p = .027). In multivariate analysis, not only local treatment for recurrent liver lesions plus chemotherapy (hazard ratio [95% confidence interval], 0.55 [0.32–0.94]; p = .030) but also indicators for systemically controlled tumor such as late recurrence (0.57 [0.35–0.92]; p = .021), chemotherapy for ≥6 months (0.25 [0.15–0.42]; p < .001), and disease control by chemotherapy (0.36 [0.22–0.60]; p < .001) were identified as favorable prognostic factors.ConclusionsPDAC patients with stable recurrent liver lesions should be considered a candidate for local treatment.